China’s Supreme People’s Court Upholds Semaglutide Patent in Major Win for Novo Nordisk
Novo Nordisk has received a significant legal victory in China’s Supreme People’s Court, which affirmed the validity of the company’s semaglutide compound patent, strengthening intellectual property protections for one of its most important medicines.










